|1.||Chebolu, Seetha: 1 article (01/2014)|
|2.||Darmani, Nissar A: 1 article (01/2014)|
|3.||Zhong, Weixia: 1 article (01/2014)|
|4.||Hutchinson, Tarun E: 1 article (01/2014)|
|5.||Scherling, Christian: 1 article (10/2013)|
|6.||Haller, Dirk: 1 article (10/2013)|
|7.||Neunlist, Michel: 1 article (10/2013)|
|8.||Baudry, Charlotte: 1 article (10/2013)|
|9.||Daniel, Hannelore: 1 article (10/2013)|
|10.||Schemann, Michael: 1 article (10/2013)|
03/21/2005 - "Moreover, it reduced the bradycardia reflex induced by 2-methyl-5-HT in anaesthetized rats. "
04/14/1997 - "Microinjections of 2-methyl-5-HT (5 nmol/50 nl) into the NTS produced a significant increase in basal mean arterial pressure (101 +/- 3 versus 125 +/- 8 mmHg), no changes in basal HR and a significant reduction in the reflex bradycardia triggered by baroreflex activation at 3 (-28 +/- 7 bpm), 10 (-35 +/- 4 bpm) and 20 min (-34 +/- 5 bpm) in comparison with the control value (-68 +/- 9 bpm). "
08/01/1995 - "Our study on the azabicycloalkaneacetamide derivatives showed that 2,3-dihydroindole as the aromatic ring moiety afforded potent 5-HT3 receptor antagonist activity, as judged by blockade of bradycardia induced by i.v. injection of 2-methylserotonin in anesthetized rats. "
09/01/2000 - "All three PDE4 inhibitors were administered at 1, 10, or 100 microg/kg (iv) 15 min prior to the induction of bradycardia by an iv injection of 2-methyl-5-HT (von Bezold-Jarisch reflex) or by vagal electrical stimulation. "
06/01/1999 - "In anaesthetized rats, i. v. administration of alosetron inhibited 2-methyl-5-HT induced bradycardia (Bezold Jarisch index) at 1 and 3 microg kg-1, with an agonist dose ratio of approximately 3.0 at 1.0 microg kg-1, = 3-5). "
06/25/1991 - "I.c.v. 2-methylserotonin was not analgesic at any dose in the pain assays employed. "
06/25/1991 - "Analgesic profile of centrally administered 2-methylserotonin against acute pain in rats."
06/25/1991 - "In contrast, only the 100 micrograms dose of 2-methylserotonin produced analgesia against thermal pain, and analgesia was not observed at any dose in the mechanical pain test. "
06/25/1991 - "The present study examined patterns of analgesia by intracerebroventricular (i.c.v.) or intrathecal (i.t.) administration of the serotonin 5-HT3 receptor agonist, 2-methylserotonin (1-100 micrograms) against acute thermal, mechanical or formalin-induced chemo-inflammatory pain in male rats. "
01/01/2014 - "Stimulation of 5-HT3 receptors (5-HT3Rs) by 2-methylserotonin (2-Me-5-HT), a selective 5-HT3 receptor agonist, can induce vomiting. "
10/04/1995 - "The 5-HT3 receptor agonist, 2-methyl-5-HT, and copper sulfate also induced emesis of short duration. "
02/01/1992 - "The 5-HT3 receptor agonists phenylbiguanide (PBG) and 2-methyl-5-HT were shown to induce vomiting and related prodromal signs (e.g., licking, swallowing) in nonoperated cats. "
11/01/1991 - "5-Hydroxytryptamine (5-HT; i.p., i.v., s.c.) and 2-methyl-5-HT (2-Me-5-HT; i.p.) but not 5-hydroxyindoleacetic acid (i.p.) or 5-methoxytryptamine (i.p.) induced emesis with very short latency. "
07/04/2003 - "However, ondansetron was more active to antagonise emesis on day 1 using a more frequent drug administration, whereas bilateral vagotomy only reduced emesis for 2 h, and 5-HT, 2-methyl-5-HT and 1-m-chloro-phenylbiguanide (up to 20-30 mg/kg, i.p.) were not emetic. "
10/01/1991 - "The agonist properties of m-chlorophenylbiguanide and 2-methyl-5-hydroxytryptamine on 5-HT3 receptors in N1E-115 neuroblastoma cells."
07/01/1995 - "Pre-incubation of the target neuroblastoma cells with several 5-HT-receptor ligands including 5-hydroxytryptamine, 8-OH-DPAT, ketanserin, 2-methyl-5-HT, as well as a number of potent 5-HT3 agonists and antagonists and two selective neurotoxins, failed to abolish the KCB action of ondansetron. "
01/01/1992 - "No hyperalgesia was seen after 5-HT1B, CGS-12066B maleate and m-trifluoromethylphenyl-piperazine hydrochloride; 5-HT2+IC, alpha methyl 5HT and (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl; or 5-HT3, 2-methyl-5-hydroxytryptamine maleate and phenylbiguanide, agonists. "
02/14/2003 - "Intrathecal application of fluvoxamine maleate and selective 5-HT receptor agonists, i.e., 8-hydroxy-2-(di-n-proplyamino)-tetralin hydrobromide (8-OH-DPAT: 5HT-1 selective) and 2-methyl-5-hydroxytryptamine maleate (2-m-5-HT: 5HT-3 selective), inhibited the spinal cord injury-induced hyperalgesia. "
|1.||bipiperidyl mustard (BPM)
|2.||5-HT3 Serotonin Receptors (5 HT3 Receptor)
|3.||Serotonin (5 Hydroxytryptamine)
|6.||5-Methoxytryptamine (5 Methoxytryptamine)
|7.||Serotonin 5-HT3 Receptor Agonists